Elevance Health, Inc. with ticker code (ELV) have now 16 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The range between the high target price and low target price is between $629.00 and $537.00 with the average share target price sitting at $577.17. (at the time of writing). Now with the previous closing price of $514.30 this is indicating there is a potential upside of 12.2%. Also worth taking note is the 50 day moving average now sits at $497.39 and the 200 day MA is $467.98. The total market capitalization for the company now stands at 119.75B. The stock price for the company is currently $514.67 USD
The potential market cap would be $134,386,170,758 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 20.41, revenue per share of $726.33 and a 5.84% return on assets.
Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefit, CarelonRx, Carelon Services, and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to individual, employer group risk-based, employer group fee-based, BlueCard, Medicare, Medicaid and federal employees health benefits (FEHB) program members. The CarelonRx segment includes its pharmacy business. CarelonRx markets and offers pharmacy services to affiliated health plan customers, as well as to external customers outside of the health plans. Carelon Services offers a broad array of healthcare-related services and capabilities to internal and external customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity services and subrogation services, as well as health and wellness programs.
